Saturday, July 5, 2025 7/5/2025

Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer

Award Number: R41CA235996
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2019
PERIOD OF PERFORMANCE END DATE: 02/28/2022

Group Awards By:

View Award Description

Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer - ABSTRACT Breast Cancer (BC) is the leading cause of cancer death for woman in the US. Breast cancer is treated by a combination of surgery, radiation, and various types of chemo and targeted therapeutic strategies. Approximately half of patients who have positive sentinel lymph nodes at surgery (and as many as 25% of patients who do not) eventually present with metastatic disease. Over 70% of BC patients eventually have skeletal involvement making bone the single most prevalent site of metastasis in BC. BioVinc has developed a novel bisphosphonate-tagged PET imaging strategy which we have shown to more thoroughly image bone disease including earlier bone effects of disease than current PET probes of other diagnostic tools. In this STTR R41 application we propose 2nd generation 18F-BP-PET imaging probes to provide breast cancer patients, a more sensitive measure of bone metastases prompting them to take advantage of new treatment strategies known to improve survival in this group. It is our goal to show that these innovative BP-PET probes can overcome some of the disadvantages of current imaging strategies for BC and provide earlier diagnosis of the bone metastases. Our innovative chemistry design offers rapid preparation (within one 18F half-life) of the proposed PET probes. Cold chemistry will be performed at the BioVinc laboratories by Dr. Frank Ebetino and the team, and then elaborated for radiochemistry requirements together with Drs. Kai Chen and Charles McKenna’s group at USC. All radiochemistry, including in situ cyclotron generation of the radioisotope 18F, as well as the in vivo animal studies and PET imaging will be performed under Dr. Kai Chen’s direction at the USC Molecular Imaging Center. We will use 18F-NaF probes as a control imaging agent in an orthotopic rodent model of breast cancer which reliably results in related bone metastases and compare them with our best novel probe for the detection of early changes in the bone due to disease. These proof of concept studies will position our research for rapid translational development in a subsequent Phase II STTR program.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	BIOVINC, LLC	1421 STATE ST STE B	SANTA BARBARA	CA	93101	SANTA BARBARA	USA	Cancer Detection and Diagnosis Research	000	1	6/9/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	BIOVINC, LLC	1421 STATE ST STE B	SANTA BARBARA	CA	93101	SANTA BARBARA	USA	Cancer Detection and Diagnosis Research	000	1	3/11/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $225,000 )
2019	2019	BIOVINC, LLC	1421 STATE ST STE B	SANTA BARBARA	CA	93101	SANTA BARBARA	USA	Cancer Detection and Diagnosis Research	000	1	8/16/2019	NEW	$225,000
														Subtotal = $225,000

Grand Total All Awards = $225,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer

Award Number: R41CA235996

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2019

PERIOD OF PERFORMANCE END DATE: 02/28/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer